Arvinas, Inc. · NASDAQ:ARVN
Arvinas — J.P. Morgan Healthcare Conference 2023
22 slides from Arvinas's conference presentation, Jan 9, 2023
Slide 1: J.P. Morgan Healthcare Conference January 11, 2023
J.P. Morgan Healthcare Conference January 11, 2023
Slide 2: Safe harbor and forward-looking statements
Safe harbor and forward-looking statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the anticipated timing of our planned clinica
Slide 3: PROTAC protein degraders combine benefits of small molecules and gene-based knockdown
3 Iterative activity PROTAC® High specificity without the requirement for strong binding PROTAC® protein degraders combine the benefits of small molecules and gene-based knockdown technologies 1. Complex Formation: Recognizing disease causing protein of interest 2. Protein Tagging: Tagging of target
Slide 4: Leaders in a new class of novel treatments
4 Consistent ability to create PROTAC® degraders with drug-like properties and signals of clinical efficacy and tolerability Creating potential therapies for patients in both oncology and neuroscience One program in a Phase 3 study, and two drug candidates in Phase 2 Partnerships with global leaders
Slide 5: Building a unique protein degradation company
Building a unique protein degradation company 5 The capabilities of our PROTAC® platform remain unmatched The deepest and most diverse pipeline of any protein degradation company Creating potential therapies in the largest areas of unmet need: Oncology and Neuroscience First in registrational studie
Slide 6: Our broad pipeline includes the first pivotal trials for PROTAC degraders
Our broad pipeline includes the first pivotal trials for PROTAC® degraders Program Therapeutic Area / Indication Preclinical Phase 1/1b Phase 2 Phase 3 ARV-471 Global co-development/ co-commercialization partners with Oncology: ER+/HER2- Breast Cancer VERITAC-2: ARV-471 monotherapy 2L pivotal trial
Slide 7: ARV-471: First-in-class ER-degrading PROTAC in advanced breast cancer
ARV-471: First-in-class Estrogen Receptor (ER)-degrading PROTAC® in advanced breast cancer ER, estrogen receptor † ACS: https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html; accessed 01/06/23 † † https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549764/, accessed 1/4/2023 7
Slide 8: ARV-471: Excellent tolerability and signals of efficacy in heavily pretreated patients
ARV-471: Excellent tolerability and signals of efficacy in the most heavily pretreated patients of any ER-targeting therapy 8 ARV-471 demonstrated strong signals of efficacy in the VERITAC Phase 2 trial Clinical Benefit Rate (Phase 2): 38% (All patients) 51% (Patients with ESR1 mutant tumors) Progre
Slide 9: Our VERITAC-2 Phase 3 pivotal trial is designed for success
Treatment (N = 560) Select Patient Eligibility Criteria Primary Endpoints • Prior CDK4/6 inhibitor treatment • No prior fulvestrant • No prior chemotherapy for locally advanced / metastatic disease Progression Free Survival (PFS) by Blinded Independent Central Review in: o ESR1 mutant population o A
Slide 10: ARV-471 clinical trials across the breast cancer treatment landscape
ARV-471 CLINICAL TRIALS ACROSS THE BREAST CANCER TREATMENT LANDSCAPE Status 3rd Line 2nd Line 1st Line Adjuvant Ongoing TACTIVE-U (Ph1B) Combination: ARV-471 + abema, ribo, and other targeted therapies Ongoing VERITAC (Ph2): ARV-471 as 2L monotherapy Ongoing VERITAC-2 (Ph3): ARV-471 as 2L monotherap
Slide 11: PROTAC degraders eliminate the androgen receptor, potentially surpassing AR inhibitors
Arvinas’ PROTAC® degraders eliminate the androgen receptor (AR), potentially surpassing the benefits of AR inhibitors 11 AR, androgen receptor 1 ACS: https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html, accessed 2/22/22; 2 American Cancer Society An AR-targeting PROTAC degrader m
Slide 12: PROTAC degraders could meet substantial unmet need across prostate cancer paradigm
Arvinas’ PROTAC® degraders could meet the substantial unmet need across the prostate cancer treatment paradigm 12 1. *Androgen Receptor 1 Decision Resources Group – Diagnosed Patients 2 Includes Castrate Sensitive Prostate Cancer, Biochemical / Recurrent Prostate Cancer, and non-mCRPC Highest Unmet
Slide 13: Bavdegalutamide shows signals of efficacy in late-line mCRPC
In Phase 2, bavdegalutamide demonstrated: • 46% PSA50 response rate in patients with AR T878X/H875Y-positive tumors • 0% Grade ≥4 TRAEs • Low rates of discontinuation and dose reduction In late-line mCRPC, bavdegalutamide has shown compelling signals of efficacy and manageable tolerability 13 Bavdeg
Slide 14: In 2023, we expect to begin a pivotal trial for bavdegalutamide
In 2023, we expect to begin a pivotal trial for bavdegalutamide and to begin AR PROTAC® investigations in pre-NHA settings 14 Androgen Receptor (AR) Franchise Clinical Trials Status Post-NHA Phase 1 Phase 2 Phase 3 Anticipated 2H23 Ongoing Ongoing Data expected 2Q23 Pre-NHA Expect to begin in 2023 A
Slide 15: The capabilities of our PROTAC platform remain unmatched
The capabilities of our PROTAC® platform remain unmatched The deepest and most diverse pipeline of any protein degradation company Arvinas’ pipeline is differentiated and sustainable 20+ Pre-clinical programs across oncology and neurodegenerative disease 4 first-in-human studies of new PROTAC® progr
Slide 16: BCL6 PROTAC degrader as first-in-class potential therapy for DLBCL
We expect our BCL6 PROTAC® degrader to be a first-in-class potential therapy for Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL, diffuse large B cell lymphoma; Ig, immunoglobulin 1 J Iqba et. al., 2007 2 Lymphoma Foundation, bit.ly/3jAni1S; 3 Figure adapted from Pasqualucci et. al., 2003 (figure at bit
Slide 17: Oral BCL6-targeting PROTAC inhibits tumor growth by nearly 100% in preclinical models
Vehicle PROTAC, 3 mpk PROTAC, 10 mpk Our oral, BCL6-targeting PROTAC® clinical candidate inhibits tumor growth by nearly 100% in preclinical models 17 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 0 200 400 600 800 1000 1200 1400 1600 1800 2000 2200 2400 2600 2800 Days of dosing M ea n Tu m or v ol (m
Slide 18: PROTAC degraders could revolutionize treatment of neurological diseases
PROTAC® degraders could revolutionize the treatment of patients with neurological diseases 18 We are creating PROTAC® degraders that can: Be delivered orally Cross the blood-brain barrier Reach targets in “deep brain” regions Degrade disease-causing proteins inside cells Significant potentia
Slide 19: PROTAC-induced LRRK2 degradation could be disease-modifying for Parkinson's Disease
PROTAC®-induced LRRK2 degradation could be a disease-modifying modality for Parkinson’s Disease 19 LRRK2 is a multidomain scaffolding kinase that contributes to PD (familial and idiopathic) • Parkinson’s Disease (PD) is the second most common neurodegenerative disease, with a diagnosed prevalence of
Slide 20: Oral PROTAC reaches deep brain regions in non-human primates and degrades LRRK2
Our oral PROTAC® clinical candidate reaches multiple “deep brain” regions in non-human primates and degrades LRRK2 20 Vehicle 5mpk Vehicle 5mpk Vehicle 5mpk >85% LRRK2 degradation in deep brain regions of cynomolgus monkeys after oral dosing LR R K 2 P ro te in (% o f V eh ic le ) 200 150 100 50 0 S
Slide 21: In the next months: 5+ clinical trial data readouts expected
21 In the next 24 months: 5+ clinical trial data readouts expected, including topline data for 1 Pivotal Trial 4 first-in-human studies of new PROTAC® programs anticipated across oncology and neuroscience 4 PIVOTAL TRIALS expected to be ongoing in breast and prostate cancer
Slide 22: Thank You
Thank You PRESS/MEDIA pr@arvinas.com INVESTORS ir@arvinas.com BUSINESS DEVELOPMENT bd@arvinas.com CAREERS careers@arvinas.com 22 For More Information